



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	I	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/227,881	/227,881 01/11/1999		THAI D. NGUYEN	07425.0057	7578
28381	7590	09/15/2004		EXAMINER	
ARNOLD			SCHULTZ, JAMES		
ATTN: IP D 555 TWELF		-· -		ART UNIT	PAPER NUMBER
WASHING	WASHINGTON, DC 20004-1206			1635	
			DATE MAILED: 09/15/2004	DATE MAILED: 09/15/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
Examiner-Initiated Interview Summary	09/227,881	NGUYEN ET AL.
Examiner-initiated interview duminary	Examiner	Art Unit
	J. D. Schultz, Ph.D.	1635
All Participants:	Status of Application:	
(1) <u>J. D. Schultz, Ph.D.</u> .	(3)	
(2) <u>Joseph Ricigliano</u> .	(4)	
Date of Interview: 14 September 2004	Time: <u>10:35 AM</u>	
Type of Interview: ☐ Telephonic ☐ Video Conference ☐ Personal (Copy given to: ☐ Applicant ☐ Applicant Exhibit Shown or Demonstrated: ☐ Yes ☐ No If Yes, provide a brief description:	ant's representative)	
Part I.		
Rejection(s) discussed: N/A		
Claims discussed: N/A		
Prior art documents discussed: N/A		
Part II.		
SUBSTANCE OF INTERVIEW DESCRIBING THE GENE See Continuation Sheet	RAL NATURE OF WHAT WAS	S DISCUSSED:
Part III.		
 ☑ It is not necessary for applicant to provide a separate of directly resulted in the allowance of the application. The of the interview in the Notice of Allowability. ☑ It is not necessary for applicant to provide a separate of did not result in resolution of all issues. A brief summar 	e examiner will provide a writtorecord of the	en summary of the substance interview, since the interview
	118 School	Sest. 14, 2018
(Examiner/SPE Signature) (Applicant	Applicant's Representative Si	gnaturé – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: In a previous interview, applicants had requested the rejoinder of claims drawn to SEQ ID NO: 34 with the claim set under examination, drawn to SEQ ID NO: 3. It was agreed that such rejoinder would be considered if it could be shown that the two sequences were related. During the instant interview, Joseph Ricigliano indicated that, on evidence of a BLASTn search, that SEQ ID NO: 34 consists of nucleotides 1-5271 of SEQ ID NO: 3. Accordingly, since SEQ ID NO: 34 is considered to be a fragment of SEQ ID NO: 3, claims drawn to both SEQ ID NOS: 3 and 34 will be examined in the next Official action...